These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 22469218)

  • 1. Benchmark dose analysis for Bacillus anthracis inhalation exposures in the nonhuman primate.
    Taft SC; Hines SA
    Risk Anal; 2012 Oct; 32(10):1750-68. PubMed ID: 22469218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the risk of mortality to primates exposed to anthrax spores.
    Haas CN
    Risk Anal; 2002 Apr; 22(2):189-93. PubMed ID: 12022669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addressing residual risk issues at anthrax cleanups: how clean is safe?
    Canter DA
    J Toxicol Environ Health A; 2005 Jun 11-25; 68(11-12):1017-32. PubMed ID: 16020189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-Response Modeling for Inhalational Anthrax in Rabbits Following Single or Multiple Exposures.
    Gutting BW; Rukhin A; Marchette D; Mackie RS; Thran B
    Risk Anal; 2016 Nov; 36(11):2031-2038. PubMed ID: 26889937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No evidence of a mild form of inhalational Bacillus anthracis infection during a bioterrorism-related inhalational anthrax outbreak in Washington, D.C., in 2001.
    Baggett HC; Rhodes JC; Fridkin SK; Quinn CP; Hageman JC; Friedman CR; Dykewicz CA; Semenova VA; Romero-Steiner S; Elie CM; Jernigan JA
    Clin Infect Dis; 2005 Oct; 41(7):991-7. PubMed ID: 16142664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-response models for inhalation of Bacillus anthracis spores: interspecies comparisons.
    Bartrand TA; Weir MH; Haas CN
    Risk Anal; 2008 Aug; 28(4):1115-24. PubMed ID: 18554269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
    Filipsson AF; Sand S; Nilsson J; Victorin K
    Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.
    Doolan DL; Freilich DA; Brice GT; Burgess TH; Berzins MP; Bull RL; Graber NL; Dabbs JL; Shatney LL; Blazes DL; Bebris LM; Malone MF; Eisold JF; Mateczun AJ; Martin GJ
    J Infect Dis; 2007 Jan; 195(2):174-84. PubMed ID: 17191162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the protective effects of quinacrine against Bacillus anthracis Ames.
    Comer JE; Noffsinger DM; McHenry DJ; Weisbaum DM; Chatuev BM; Chopra AK; Peterson JW
    J Toxicol Environ Health A; 2006 Jun; 69(11):1083-95. PubMed ID: 16840255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
    Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
    Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Setting risk-informed environmental standards for Bacillus anthracis spores.
    Hong T; Gurian PL; Ward NF
    Risk Anal; 2010 Oct; 30(10):1602-22. PubMed ID: 20626695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling Rabbit Responses to Single and Multiple Aerosol Exposures of Bacillus anthracis Spores.
    Coleman ME; Marks HM; Bartrand TA; Donahue DW; Hines SA; Comer JE; Taft SC
    Risk Anal; 2017 May; 37(5):943-957. PubMed ID: 28121020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction to benchmark dose methods and U.S. EPA's benchmark dose software (BMDS) version 2.1.1.
    Davis JA; Gift JS; Zhao QJ
    Toxicol Appl Pharmacol; 2011 Jul; 254(2):181-91. PubMed ID: 21034758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Airborne infection with Bacillus anthracis--from mills to mail.
    Fennelly KP; Davidow AL; Miller SL; Connell N; Ellner JJ
    Emerg Infect Dis; 2004 Jun; 10(6):996-1002. PubMed ID: 15207048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacillus anthracis contamination and inhalational anthrax in a mail processing and distribution center.
    Sanderson WT; Stoddard RR; Echt AS; Piacitelli CA; Kim D; Horan J; Davies MM; McCleery RE; Muller P; Schnorr TM; Ward EM; Hales TR
    J Appl Microbiol; 2004; 96(5):1048-56. PubMed ID: 15078521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the incubation period of inhalational anthrax.
    Wilkening DA
    Med Decis Making; 2008; 28(4):593-605. PubMed ID: 18556642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim guidelines for investigation of and response to Bacillus anthracis exposures.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(44):987-90. PubMed ID: 11724154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrated experimental-computational approach for predicting virulence in New Zealand white rabbits and humans following inhalation exposure to Bacillus anthracis spores.
    Hess BM; Thomas DG; Weber TJ; Hutchison JR; Straub TM; Bruckner-Lea CJ; Powell JD; Kabilan S; Corley RA
    PLoS One; 2019; 14(7):e0219160. PubMed ID: 31260462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model for in-vivo delivered dose estimation for inhaled bacillus anthracis spores in humans with interspecies extrapolation.
    Weir MH; Haas CN
    Environ Sci Technol; 2011 Jul; 45(13):5828-33. PubMed ID: 21667964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Inhaled Versus Deposited Dose Using the Exponential Dose-Response Model for Inhalational Anthrax in Nonhuman Primate, Rabbit, and Guinea Pig.
    Gutting BW; Rukhin A; Mackie RS; Marchette D; Thran B
    Risk Anal; 2015 May; 35(5):811-27. PubMed ID: 25545587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.